Changes in biochemical and coagulological blood tests in patients with bronchial asthma who underwent COVID-19

Objective. To study the dynamics of changes in indicators of biochemical blood analysis and markers of the state of hemostasis and fibrinolysis systems in patients with previously treated bronchial asthma (BA) of moderate severity who had and did not have COVID-19 before and during treatment. Material and methods. The study included 58 patients who were divided into two groups: 1st (BA/COVID-19; n=29) – patients with BA who had undergone COVID-19; 2st (BA; n=29) – patients with BA who had not undergone COVID-19. Markers of impaired liver function, lipid metabolism, as well as a marker of systemic inflammation, C-reactive protein, were studied. The condition of the plasma, antiserum and fibrinolytic systems was assessed. Laboratory tests were performed before the start of treatment and upon discharge from the hospital. Results. Before the start of treatment, changes in liver function and lipid metabolism were more often detected in the group of patients with BA/COVID-19. By the end of the follow-up, the proportion of patients with laboratory manifestations of cytolysis and lipid metabolism disorders increased more significantly in the BA/COVID-19 group. At the same time, the number of patients with cholestasis phenomena in the BA group decreased significantly, and in the BA/COVID-19 group increased slightly. Hypercoagulation shift was significantly more often detected in the group of patients with BA/COVID-19 and by the end of the follow-up, the number of such patients increased, and in the BA group their number significantly decreased. Before the start of treatment, systemic inflammation was observed in most patients, by the end of the follow-up, the number of such patients in both groups decreased, but in the BA/COVID-19 group, the proportion of such patients was significantly higher.